What Glaukos (GKOS)'s Stephen Curry Keratoconus Campaign Means For Shareholders

• Glaukos recently launched the "Could it be KC?" disease awareness and education campaign with NBA champion Stephen Curry to improve recognition and earlier detection of keratoconus, a progressive, sight-threatening corneal disorder.
• The campaign places Glaukos closer to the front line of keratoconus education. This positioning could strengthen demand for its corneal health portfolio and related services among patients, families, and eye care professionals.
• We will explore how Glaukos' investment narrative is shaped by this Stephen Curry backed keratoconus awareness push and its broader corneal ambitions.

Scan beyond Glaukos and this keratoconus push by lining up similar high-conviction health stocks. Use our curated 38 healthcare AI stocks for ideas with real medical problem solving at the center.

Glaukos Investment Narrative Recap

To own Glaukos, you need to believe it can turn its glaucoma, corneal and retinal platforms into a durable, procedure based ophthalmology franchise while moving from losses to sustainable profitability. The key near term swing factor remains execution on iDose TR adoption and reimbursement, since a higher mix of this product is already linked with stronger gross margins.

The biggest risk is still pressure on procedure volumes and fees, given exposure to CMS decisions and private payer behavior. The Stephen Curry keratoconus campaign likely does not alter that near term risk reward balance in a material way, although it can support longer term corneal demand.

The most relevant announcement around this keratoconus push is Glaukos' investment into corneal health, including iLink and the planned transition from Photrexa to Epioxa. The "Could it be KC?" effort supports that direction by widening the funnel of patients who get diagnosed earlier and may be candidates for intervention.

For catalysts, investors are watching whether corneal programs can become a second engine next to iDose TR and the iStent family. Execution risks remain real, from reimbursement uptake to trial timelines, and the stock already trades on a rich price-to-sales multiple relative to peers, which can amplify any disappointment around those milestones.

Glaukos’ current analyst narrative points to forecast revenues of US$1.2b and earnings of US$132.4 million by 2029. This outlook is built on an assumed 24.9% yearly revenue growth rate and an earnings swing of roughly US$320.4 million, from a loss of US$188.0 million today to that 2029 consensus figure.

Uncover why Glaukos' fair value indicates a 27% potential upside to its current price, a discount that could narrow more quickly than many investors expect.

Exploring Other Perspectives

One alternate angle puts Glaukos’ corneal catalyst front and center. Bullish analysts already modeled about US$1.5b of revenue and US$221.4 million of earnings by 2029 before this Stephen Curry keratoconus push. You can view this campaign as a potential accelerant to that earlier corneal optimism, or as a reason to rethink those top-end assumptions entirely.

Explore 3 other Glaukos fair value estimates, including one that suggests as much as 143% potential upside from the current price.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Glaukos research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Glaukos. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Glaukos' overall financial health at a glance.

Looking For More Ideas Beyond Glaukos?

If Glaukos has you thinking more broadly about where to put fresh capital to work, it can help to line up a few very different types of opportunities side by side. That way you are comparing trade offs on quality, risk and income potential rather than chasing the loudest headline.

The Simply Wall St Screener gives you a simple way to do that in a few clicks. Start by shortlisting a handful of focused stock lists, then pressure test which ones actually fit your own goals and risk tolerance.

• For investors hunting for smaller companies with punchy upside potential, scan a curated group of 8 elite penny stocks with strong financials that already clear a basic financial quality bar.
• If value and balance sheet strength matter more than excitement, line up a 30 high quality undervalued stocks shortlist where cash generation and pricing both look more conservative.
• For those who care most about resilience and sleeping well at night, filter for 30 resilient stocks with low risk scores and focus on businesses flagged for relatively lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com